{"id":"sodium-benzoate","rwe":[],"_fda":{"id":"fd646c47-7fcd-4d60-8f6c-29e13f611c6d","set_id":"0f17c50f-3761-4470-bf3b-63837a287b8a","openfda":{"upc":["0370710192617"],"unii":["OJ245FE5EU","48N6U1781G"],"route":["INTRAVENOUS"],"rxcui":["2560228"],"spl_id":["fd646c47-7fcd-4d60-8f6c-29e13f611c6d"],"brand_name":["Sodium phenylacetate and Sodium benzoate"],"spl_set_id":["0f17c50f-3761-4470-bf3b-63837a287b8a"],"package_ndc":["70710-1926-1"],"product_ndc":["70710-1926"],"generic_name":["SODIUM PHENYLACETATE AND SODIUM BENZOATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SODIUM BENZOATE","SODIUM PHENYLACETATE"],"manufacturer_name":["Zydus Pharmaceuticals USA Inc."],"application_number":["ANDA217526"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Risk Summary Available data on the combination use of Sodium Phenylacetate and Sodium Benzoate in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."],"overdosage":["10 OVERDOSAGE Overdosage has been reported during Sodium Phenylacetate and Sodium Benzoate Injection treatment in urea cycle-deficient patients. All patients in the uncontrolled open-label study were to be treated with the same dose of Sodium Phenylacetate and Sodium Benzoate Injection. However, some patients received more than the dose level specified in the protocol. In 16 of the 64 deaths, the patient received a known overdose of Sodium Phenylacetate and Sodium Benzoate Injection. Causes of death in these patients included cardiorespiratory failure/arrest (6 patients), hyperammonemia (3 patients), increased intracranial pressure (2 patients), pneumonitis with septic shock and coagulopathy (1 patient), error in dialysis procedure (1 patient), respiratory failure (1 patient), intractable hypotension and probable sepsis (1 patient), and unknown (1 patient). Additionally, other signs of intoxication may include obtundation (in the absence of hyperammonemia), hyperventilation, a severe compensated metabolic acidosis, perhaps with a respiratory component, large anion gap, hypernatremia and hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and death. In case of overdose of Sodium Phenylacetate and Sodium Benzoate Injection, discontinue the drug and institute appropriate emergency medical monitoring and procedures. In severe cases, the latter may include hemodialysis (procedure of choice) or peritoneal dialysis (when hemodialysis is unavailable)."],"description":["11 DESCRIPTION Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% (a nitrogen binding agent), is a sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. The pH of the solution is between 7.0 and 8.0. Sodium phenylacetate is a white to off-white powder. It is soluble in water. Sodium benzoate is a white to off-white powder that is readily soluble in water. Figure 1 Sodium phenylacetate has a molecular weight of 158.14 and the molecular formula C 8 H 7 NaO 2 . Sodium benzoate has a molecular weight of 144.10 and the molecular formula C 7 H 5 NaO 2 . Each mL of Sodium Phenylacetate and Sodium Benzoate Injection contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, and Water for Injection. Sodium hydroxide and/or hydrochloric acid may have been used for pH adjustment. Sodium Phenylacetate and Sodium Benzoate Injection is a sterile, concentrated solution intended for intravenous administration via a central venous catheter only after dilution [ see Dosage and Administration (2) ]. structure-figure-01"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% is clear and almost colorless solution supplied in a sterile, non-pyrogenic, single-dose glass vial. NDC 70710-1926-1 single-dose vial containing 20 mL of Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10%. Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."],"geriatric_use":["8.5 Geriatric Use Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population."],"pediatric_use":["8.4 Pediatric Use Sodium Phenylacetate and Sodium Benzoate Injection has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [ see Dosage and Administration (2) ]."],"effective_time":"20231030","nursing_mothers":["8.2 Lactation Risk Summary There are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Sodium Phenylacetate and Sodium Benzoate Injection and any potential adverse effects on the breastfed infant from Sodium Phenylacetate and Sodium Benzoate Injection or from the underlying maternal condition."],"clinical_studies":["14 CLINICAL STUDIES The efficacy of Sodium Phenylacetate and Sodium Benzoate Injection in improving patient survival of acute hyperammonemic episodes was demonstrated in an analysis of 316 patients (1045 episodes of hospitalization) treated between 1981 and 2003. The demographic characteristics and diagnoses of the patient population are shown in Table 3. Table 3: Baseline Characteristics and Diagnoses of Study Population OTC = ornithine transcarbamylase deficiency ASS = argininosuccinate synthetase deficiency CPS = carbamyl phosphate synthetase deficiency ASL = argininosuccinate lyase deficiency ARG = arginase deficiency THN = transient hyperammonemia of the newborn * For the summary at the patient level, data obtained at first episode used. ** Diagnosis unknown or pending (33 episodes), acidemia (14 episodes), HHH syndrome (6 episodes), carnitine translocase deficiency (4 episodes), liver disease (3 episodes), HMG CoA lyase deficiency (1 episode), non-ketotic hyperglycinemia (1 episode), suspected fatty acid oxidation deficiency (1 episode), and valproic-acid-induced hyperammonemia (1 episode). Patients * N=316 Gender Male 158 (51%) Female 150 (49%) N 310 Age (years) Mean (SD) 6.2 (8.54) Min–Max 0.0–53.0 0–30 days 104 (34%) 31 days–2 years 55 (18%) Age groups > 2–12 years 90 (29%) > 12–16 years 30 (10%) > 16 years 31 (10%) OTC 146 (46%) ASS 71 (22%) CPS 38 (12%) Enzyme deficiency ASL 7 (2%) ARG 2 (< 1%) THN 2 (< 1%) Other ** 56 (18%) On admission to the hospital, patients with hyperammonemia and a suspected or confirmed urea cycle disorder (UCD) diagnosis were treated with a bolus dose of 0.25 g/kg (or 5.5 g/m 2 ) sodium phenylacetate + 0.25 g/kg (or 5.5 g/m 2 ) sodium benzoate over a period of 90 minutes to 6 hours, depending on the specific UCD. Infusions also contained arginine; the dose of arginine depended on the specific UCD. After completion of the bolus dose, maintenance infusions of the same dose over 24 hours were continued until the patient was no longer hyperammonemic or oral therapy could be tolerated. The mean (SD) duration of treatment was 4.6 (6.45) days per episode, and ranged from 1 to 72 days. Survival was substantially improved after Sodium Phenylacetate and Sodium Benzoate Injection treatment compared with historical values (estimated 14% 1-year survival rate with dietary therapy alone) and with dialysis (estimated 43% survival of acute hyperammonemia). Eighty percent of patients (252 of 316) survived their last episode. Of the 64 patients who died, 53 (83%) died during their first hyperammonemic episode. Of the 104 neonates (<30d) treated with Sodium Phenylacetate and Sodium Benzoate Injection, 34 (33%) died during the first hyperammonemic episode. Ammonia levels decreased from very high levels (>4 times the upper limit of normal [ULN]) to lower levels in 91% of episodes after treatment. In patients responding to therapy, mean ammonia concentrations decreased from 200.9 umol/L at hour zero to 101.6 umol/L within four hours of initiation of Sodium Phenylacetate and Sodium Benzoate Injection therapy and were maintained. Hemodialysis is recommended for those patients whose plasma ammonia levels fail to fall below 150 µmol/L or by more than 40% within 4 to 8 hours after receiving Sodium Phenylacetate and Sodium Benzoate Injection. A shift from high (≤4 times ULN) to very high (>4 times ULN) levels was observed in only 4% of the episodes. Overall, investigators rated neurological status as improved, much improved, or the same in 93% of episodes, and overall status in response to treatment as improved, much improved, or the same in 97% of episodes. Recovery from coma was observed in 97% of episodes where coma was present at admission (111 of 114 episodes)."],"pharmacodynamics":["12.2 Pharmacodynamics In patients with hyperammonemia due to deficiencies in enzymes of the urea cycle, Sodium Phenylacetate and Sodium Benzoate Injection has been shown to decrease elevated plasma ammonia levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by Sodium Phenylacetate and Sodium Benzoate Injection in combination with appropriate dietary and other supportive measures."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of intravenously administered Sodium Phenylacetate and Sodium Benzoate Injection was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC last for benzoate was 20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 5.19 to 3.62 L/h/m 2 at the 3.75 and 5.5 g/m 2 doses, respectively. Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens. AUC last was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg⋅h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 1.82 to 0.89 mcg⋅h/mL with increasing dose (3.75 and 4 g/m 2 , respectively). During the sequence of 90 minute priming infusion followed by a 24 hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T max of 2 hr at 3.75 g/m 2 ) whereas, benzoate concentrations declined rapidly (T max of 1.5 hr at 3.75 g/m 2 ) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m 2 dose, respectively. A difference in the metabolic rates for phenylacetate and benzoate was noted. The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine. Pharmacokinetic observations have also been reported from twelve episodes of hyperammonemic encephalopathy in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered Sodium Phenylacetate and Sodium Benzoate Injection intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults. As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time. The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced solid tumors. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine."],"adverse_reactions":["6 ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥ 6%) are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534 at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data were obtained from 316 patients who received Sodium Phenylacetate and Sodium Benzoate Injection as emergency (rescue) or prospective treatment for hyperammonemia as part of an uncontrolled, open-label study. The study population included patients between the ages of 0 to 53 years with a mean (SD) of 6.2 (8.54) years; 51% were male and 49% were female who had the following diagnoses: OTC (46%), ASS (22%), CPS (12%), ASL (2%), ARG (<1%), THN (<1%), and other (18%). Adverse reactions were reported with similar frequency in patients with OTC, ASS, CPS, and diagnoses categorized as \"other.\" Nervous system disorders were more frequent in patients with OTC and CPS, compared with patients with ASS and patients with \"other\" diagnoses. Convulsions and mental impairment were reported in patients with OTC and CPS. These observations are consistent with literature reports that patients with enzyme deficiencies occurring earlier in the urea cycle (i.e., OTC and CPS) tend to be more severely affected. Adverse reactions profiles differed by age group. Patients ≤30 days of age had more blood and lymphatic system disorders and vascular disorders (specifically hypotension), while patients > 30 days of age had more gastrointestinal disorders (specifically nausea, vomiting and diarrhea). Less common adverse reactions (<3% of patients) that are characterized as severe are listed below by body system. BLOOD AND LYMPHATIC SYSTEM DISORDERS: coagulopathy, pancytopenia, thrombocytopenia. CARDIAC DISORDERS: atrial rupture, bradycardia, cardiac or cardiopulmonary arrest/failure, cardiogenic shock, cardiomyopathy, pericardial effusion. EYE DISORDERS: blindness. GASTROINTESTINAL DISORDERS: abdominal distension, gastrointestinal hemorrhage. GENERAL DISORDERS AND ADMINISTRATION-SITE CONDITIONS: asthenia, brain death, chest pain, multiorgan failure, edema. HEPATOBILIARY DISORDERS: cholestasis, hepatic artery stenosis, hepatic failure/hepatotoxicity, jaundice. INFECTIONS AND INFESTATIONS: sepsis/septic shock. INJURY, POISONING AND PROCEDURAL COMPLICATIONS: brain herniation, subdural hematoma, overdose. INVESTIGATIONS: blood carbon dioxide changes, blood glucose changes, blood pH increased, cardiac output decreased, pCO 2 changes, respiratory rate increased. METABOLISM AND NUTRITION DISORDERS: alkalosis, dehydration, fluid overload/retention, hypoglycemia, hyperkalemia, hypernatremia, alkalosis, tetany. NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED: hemangioma acquired. NERVOUS SYSTEM DISORDERS: areflexia, ataxia, brain infarction, brain hemorrhage, cerebral atrophy, clonus, depressed level of consciousness, encephalopathy, nerve paralysis, intracranial pressure increased, subdural hematoma, tremor. PSYCHIATRIC DISORDERS: acute psychosis, aggression, confusional state, hallucinations. RENAL AND URINARY DISORDERS: anuria, renal failure, urinary retention. RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS: acute respiratory distress syndrome, dyspnea, hypercapnia, hyperventilation, Kussmaul respiration, pneumonia aspiration, pneumothorax, pulmonary hemorrhage, pulmonary edema, respiratory acidosis or alkalosis, respiratory arrest/failure. SKIN AND SUBCUTANEOUS TISSUE DISORDERS: alopecia, blister, pruritus generalized, rash, urticarial. VASCULAR DISORDERS: flushing, hemorrhage, hypertension, phlebothrombosis/thrombosis. Table 2 : Adverse Reactions Occurring in ≥3% of Patients Treated with Sodium Phenylacetate and Sodium Benzoate Injection Patients N=316 Number of patients with any adverse event 163 (52%) Blood and lymphatic system disorders 35 (11%) Anemia 12 (4%) Disseminated intravascular coagulation 11 (3%) Cardiac disorders 28 (9%) Gastrointestinal disorders 42 (13%) Diarrhea 10 (3%) Nausea 9 (3%) Vomiting 29 (9%) General disorders and administration-site conditions 45 (14%) Injection-site reaction 11 (3%) Pyrexia 17 (5%) Infections 39 (12%) Urinary tract infection 9 (3%) Injury, poisoning and procedural complications 12 (4%) Investigations 32 (10%) Metabolism and nutrition disorders 67 (21%) Acidosis 8 (3%) Hyperammonemia 17 (5%) Hyperglycemia 22 (7%) Hypocalcemia 8 (3%) Hypokalemia 23 (7%) Metabolic acidosis 13 (4%) Nervous system disorders 71 (22%) Brain edema 17 (5%) Coma 10 (3%) Convulsions 19 (6%) Mental impairment 18 (6%) Psychiatric disorders 16 (5%) Agitation 8 (3%) Renal and urinary disorders 14 (4%) Respiratory, thoracic and mediastinal disorders 47 (15%) Respiratory distress 9 (3%) Skin and subcutaneous tissue disorders 19 (6%) Vascular disorders 19 (6%) Hypotension 14 (4%)"],"contraindications":["4 CONTRAINDICATIONS None ( 4 ) None."],"drug_interactions":["7 DRUG INTERACTIONS Some antibiotics such as penicillin may affect the overall disposition of the infused drug. ( 7 ) Probenecid may affect renal excretion of phenylacetylglutamine and hippurate. ( 7 ) Valproic acid given to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. ( 7 ) Use of corticosteroids may cause the breakdown of body protein and potentially increase plasma ammonia levels in patients with impaired ability to form urea. ( 7 ) Formal drug interaction studies have not been performed with Sodium Phenylacetate and Sodium Benzoate Injection. Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of N -acetylglutamate, a co-factor for carbamyl phosphate synthetase. Therefore, administration of valproic acid to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection. Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea."],"mechanism_of_action":["12.1 Mechanism of Action Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine. Figure 2 CPS = carbamyl phosphate synthetase; OTC = ornithine transcarbamylase; ASS = argininosuccinate synthetase; ASL = argininosuccinate lyase; ARG = arginase; NAGS = N -acetylglutamate synthetase"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine. Figure 2 CPS = carbamyl phosphate synthetase; OTC = ornithine transcarbamylase; ASS = argininosuccinate synthetase; ASL = argininosuccinate lyase; ARG = arginase; NAGS = N -acetylglutamate synthetase 12.2 Pharmacodynamics In patients with hyperammonemia due to deficiencies in enzymes of the urea cycle, Sodium Phenylacetate and Sodium Benzoate Injection has been shown to decrease elevated plasma ammonia levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by Sodium Phenylacetate and Sodium Benzoate Injection in combination with appropriate dietary and other supportive measures. 12.3 Pharmacokinetics The pharmacokinetics of intravenously administered Sodium Phenylacetate and Sodium Benzoate Injection was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC last for benzoate was 20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 5.19 to 3.62 L/h/m 2 at the 3.75 and 5.5 g/m 2 doses, respectively. Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens. AUC last was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg⋅h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 1.82 to 0.89 mcg⋅h/mL with increasing dose (3.75 and 4 g/m 2 , respectively). During the sequence of 90 minute priming infusion followed by a 24 hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T max of 2 hr at 3.75 g/m 2 ) whereas, benzoate concentrations declined rapidly (T max of 1.5 hr at 3.75 g/m 2 ) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m 2 dose, respectively. A difference in the metabolic rates for phenylacetate and benzoate was noted. The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine. Pharmacokinetic observations have also been reported from twelve episodes of hyperammonemic encephalopathy in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered Sodium Phenylacetate and Sodium Benzoate Injection intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults. As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time. The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced solid tumors. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine. moa-figure-02"],"indications_and_usage":["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Decreased Potassium Levels: Plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. ( 5.1 ) Conditions Associated with Fluid Overload: Sodium Phenylacetate and Sodium Benzoate Injection contains 30.5 mg of sodium per mL of undiluted product. Caution should be used if Sodium Phenylacetate and Sodium Benzoate Injection is administered to patients with congestive heart failure, severe renal insufficiency, or with conditions in which there is sodium retention with edema. ( 5.2 ) Extravasation: Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection into the perivenous tissues during high flow bolus infusion may lead to skin necrosis, especially in infants. The infusion site must be monitored closely for possible tissue infiltration during drug administration. ( 5.3 ) Neurotoxicity of Phenylacetate: Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. Additionally, neurotoxicity related to phenylacetate has been reported in cancer patients. Monitor patients for symptoms of acute neurotoxicity.( 5.4 ) Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. Monitor patient blood chemistry profiles and perform frequent blood pH and pCO 2 measurements. ( 5.5 ) 5.1 Decreased Potassium Levels Because urine potassium loss is enhanced by the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate, plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. 5.2 Conditions Associated with Fluid Overload Sodium Phenylacetate and Sodium Benzoate Injection contains 30.5 mg of sodium per mL of undiluted product. Thus, Sodium Phenylacetate and Sodium Benzoate Injection should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. Discontinue administration of Sodium Phenylacetate and Sodium Benzoate Injection, evaluate the patient, and institute appropriate therapeutic countermeasures if an adverse event occurs. 5.3 Extravasation Administration must be through a central venous catheter. Administration through a peripheral line may cause burns . Bolus infusion flow rates are relatively high, especially for infants [ see Dosage and Administration (2) ]. Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection into the perivenous tissues may lead to skin necrosis. If extravasation is suspected, discontinue the infusion and resume at a different infusion site, if necessary. The infusion site must be monitored closely for possible infiltration during drug administration. Do not administer undiluted product. 5.4 Neurotoxicity of Phenylacetate Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection should not be administered. Additionally, neurotoxicity was reported in cancer patients receiving intravenous phenylacetate, 250–300 mg/kg/day for 14 days, repeated at 4-week intervals. Manifestations were predominantly somnolence, fatigue, and lightheadedness, with less frequent headaches, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of a pre-existing neuropathy. The acute onset of symptoms upon initiation of treatment and reversibility of symptoms when the phenylacetate was discontinued suggest a drug effect [ See Animal Toxicology and/or Pharmacology (13.2) ]. 5.5 Hyperventilation and Metabolic Acidosis Due to structural similarities between phenylacetate and benzoate to salicylate, Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. Monitoring of blood chemistry profiles, blood pH and pCO 2 should be performed."],"clinical_studies_table":["
Table 3: Baseline Characteristics and Diagnoses of Study Population
OTC = ornithine transcarbamylase deficiency
ASS = argininosuccinate synthetase deficiency
CPS = carbamyl phosphate synthetase deficiency
ASL = argininosuccinate lyase deficiency
ARG = arginase deficiency
THN = transient hyperammonemia of the newborn
*For the summary at the patient level, data obtained at first episode used.
**Diagnosis unknown or pending (33 episodes), acidemia (14 episodes), HHH syndrome (6 episodes), carnitine translocase deficiency (4 episodes), liver disease (3 episodes), HMG CoA lyase deficiency (1 episode), non-ketotic hyperglycinemia (1 episode), suspected fatty acid oxidation deficiency (1 episode), and valproic-acid-induced hyperammonemia (1 episode).
Patients* N=316
Gender Male 158 (51%)
Female 150 (49%)
N 310
Age (years) Mean (SD) 6.2 (8.54)
Min–Max 0.0–53.0
0–30 days 104 (34%)
31 days–2 years 55 (18%)
Age groups > 2–12 years 90 (29%)
> 12–16 years 30 (10%)
> 16 years 31 (10%)
OTC 146 (46%)
ASS 71 (22%)
CPS 38 (12%)
Enzyme deficiency ASL 7 (2%)
ARG 2 (< 1%)
THN 2 (< 1%)
Other** 56 (18%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Sodium Phenylacetate and Sodium Benzoate Injection. Studies to evaluate the possible impairment of fertility or mutagenic potential of Sodium Phenylacetate and Sodium Benzoate Injection have not been performed. Results indicate that sodium benzoate is not mutagenic or carcinogenic and does not impair fertility. 13.2 Animal Toxicology and/or Pharmacology In animal studies, subcutaneous administration to rat pups of 190–474 mg/kg of phenylacetate caused decreased proliferation and increased loss of neurons, and reduced central nervous system (CNS) myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth. Pregnant rats were given phenylacetate at 3.5 μmol/g/day subcutaneously from gestation day 7 through normal delivery. Prenatal exposure of rat pups to phenylacetate produced lesions in layer 5 cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number."],"adverse_reactions_table":["
Table 2 : Adverse Reactions Occurring in ≥3% of Patients Treated with Sodium Phenylacetate and Sodium Benzoate Injection
Patients N=316
Number of patients with any adverse event 163 (52%)
Blood and lymphatic system disorders 35 (11%)
Anemia 12 (4%)
Disseminated intravascular coagulation 11 (3%)
Cardiac disorders 28 (9%)
Gastrointestinal disorders 42 (13%)
Diarrhea 10 (3%)
Nausea 9 (3%)
Vomiting 29 (9%)
General disorders and administration-site conditions 45 (14%)
Injection-site reaction 11 (3%)
Pyrexia 17 (5%)
Infections 39 (12%)
Urinary tract infection 9 (3%)
Injury, poisoning and procedural complications 12 (4%)
Investigations 32 (10%)
Metabolism and nutrition disorders 67 (21%)
Acidosis 8 (3%)
Hyperammonemia 17 (5%)
Hyperglycemia 22 (7%)
Hypocalcemia 8 (3%)
Hypokalemia 23 (7%)
Metabolic acidosis 13 (4%)
Nervous system disorders 71 (22%)
Brain edema 17 (5%)
Coma 10 (3%)
Convulsions 19 (6%)
Mental impairment 18 (6%)
Psychiatric disorders 16 (5%)
Agitation 8 (3%)
Renal and urinary disorders 14 (4%)
Respiratory, thoracic and mediastinal disorders 47 (15%)
Respiratory distress 9 (3%)
Skin and subcutaneous tissue disorders 19 (6%)
Vascular disorders 19 (6%)
Hypotension 14 (4%)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Physicians should advise patients and caregivers about the following for safe use of Sodium Phenylacetate and Sodium Benzoate Injection: When plasma ammonia levels have normalized, dietary protein intake can usually be increased with the goal of unrestricted protein intake. The most common adverse reactions are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. Generally BUPHENYL is stopped during the time Sodium Phenylacetate and Sodium Benzoate Injection is used."],"spl_unclassified_section":["Distributed by: Zydus Pharmaceuticals USA Inc. Pennington NJ 08534 30190323 R0"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. Administration must be through a central venous catheter. Administration through a peripheral line may cause burns. ( 2 ) Sodium Phenylacetate and Sodium Benzoate Injection is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours. ( 2 ) See Full Prescribing Information for complete dosing recommendations. 2.1 Recommended Dosage Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. The dilution and dosage of Sodium Phenylacetate and Sodium Benzoate Injection are determined by weight for neonates, infants and young children, and by body surface area for larger patients, including older children, adolescents, and adults (Table 1). Table 1: Dosage and Administration Abbreviations: CPS - carbamyl phosphate synthetase; OTC - ornithine transcarbamylase; ASS - argininosuccinate synthetase; ASL - argininosuccinate lyase Patient Population Components of Infusion Solution Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection at ≥ 25 mL/Kg before administration. Dosage Provided Sodium Phenylacetate and Sodium Benzoate Injection Arginine HCl Injection, 10% Sodium Phenylacetate Sodium Benzoate Arginine HCl CPS and OTC Deficiency Patients 0 to 20 kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 2 mL/kg 250 mg/kg 250 mg/kg 200 mg/kg ASS and ASL Deficiency Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 6 mL/kg 250 mg/kg 250 mg/kg 600 mg/kg CPS and OTC Deficiency Patient>20kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m 2 2 mL/kg 5.5g/m 2 5.5 g/m 2 200 mg/kg ASS and ASL Deficiency Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m 2 6 mL/kg 5.5 g/m 2 5.5 g/m 2 600 mg/kg 2.2 Administration Sodium Phenylacetate and Sodium Benzoate Injection is a concentrated solution and must be diluted before intravenous administration via a central venous catheter. Administration through a peripheral intravenous catheter may cause burns. Sodium Phenylacetate and Sodium Benzoate Injection may not be administered by any other route. Sodium Phenylacetate and Sodium Benzoate Injection should be administered as a loading dose infusion over 90 to 120 minutes, followed by the same dose repeated as a maintenance infusion administered over 24 hours. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection should not be administered. Maintenance infusions may be continued until elevated plasma ammonia levels have been normalized or the patient can tolerate oral nutrition and medications. An antiemetic may be administered during Sodium Phenylacetate and Sodium Benzoate Injection infusion to aid control of infusion-associated nausea and vomiting. Administration of analogous oral drugs, such as sodium phenylbutyrate, should be terminated prior to Sodium Phenylacetate and Sodium Benzoate Injection infusion. Sodium Phenylacetate and Sodium Benzoate Injection infusion should be started as soon as the diagnosis of hyperammonemia is made. Treatment of hyperammonemia also requires caloric supplementation and restriction of dietary protein. Non-protein calories should be supplied principally as glucose (8–10 mg/kg/min) with an intravenous fat emulsion added. Attempts should be made to maintain a caloric intake of greater than 80 kcal/kg/day. During and after infusion of Sodium Phenylacetate and Sodium Benzoate Injection, ongoing monitoring of the following clinical laboratory values is crucial: plasma ammonia, glutamine, quantitative plasma amino acids, blood glucose, electrolytes, venous or arterial blood gases, AST and ALT. On-going monitoring of the following clinical responses is also crucial to assess patient response to treatment: neurological status, Glasgow Coma Scale, tachypnea, CT or MRI scan or fundoscopic evidence of cerebral edema, and/or of gray matter and white matter damage. Hemodialysis should be considered in patients with severe hyperammonemia or who are not responsive to Sodium Phenylacetate and Sodium Benzoate Injection administration [ see Warnings and Precautions (5.1) ]. In the non-neonatal study patient population treated with Sodium Phenylacetate and Sodium Benzoate Injection, dialysis was required in 13% of hyperammonemic episodes. Standard hemodialysis was the most frequently used dialysis method. High levels of ammonia can be reduced quickly when Sodium Phenylacetate and Sodium Benzoate Injection is used with hemodialysis, as the ammonia-scavenging of Sodium Phenylacetate and Sodium Benzoate Injection suppresses the production of ammonia from catabolism of endogenous protein and hemodialysis eliminates the ammonia and ammonia conjugates. Sodium Phenylacetate and Sodium Benzoate Injection solutions are physically and chemically stable for up to 24 hours at room temperature and room lighting conditions. No compatibility information is presently available for Sodium Phenylacetate and Sodium Benzoate Injection infusion solutions except for Arginine HCl Injection, 10%, which may be mixed in the same container as Sodium Phenylacetate and Sodium Benzoate Injection. Other infusion solutions and drug products should not be administered together with Sodium Phenylacetate and Sodium Benzoate Injection infusion solution. Sodium Phenylacetate and Sodium Benzoate Injection solutions may be prepared in glass and PVC containers. Arginine Administration Intravenous arginine is an essential component of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency. Because hyperchloremic acidosis may develop after high-dose arginine hydrochloride administration, chloride and bicarbonate levels should be monitored and appropriate amounts of bicarbonate administered. In hyperammonemic infants with suspected, but unconfirmed urea cycle disorders, intravenous arginine should be given (6 mL/kg of Arginine HCl Injection 10%, over 90 minutes followed by the same dose given as a maintenance infusion over 24 hours). If deficiencies of ASS or ASL are excluded as diagnostic possibilities, the intravenous dose of arginine HCl should be reduced to 2 mL/kg/day Arginine HCl Injection 10%. Converting To Oral Treatment Once elevated ammonia levels have been reduced to the normal range, oral therapy, such as sodium phenylbutyrate, dietary management and maintenance protein restrictions should be started or reinitiated."],"spl_product_data_elements":["Sodium phenylacetate and Sodium benzoate Sodium phenylacetate and Sodium benzoate SODIUM PHENYLACETATE PHENYLACETIC ACID SODIUM BENZOATE BENZOIC ACID WATER SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 10% per 10% sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. ( 3 ) Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% is a sterile, clear and almost colorless concentrated, aqueous solution of sodium phenylacetate and sodium benzoate."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data on the combination use of Sodium Phenylacetate and Sodium Benzoate in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Sodium Phenylacetate and Sodium Benzoate Injection and any potential adverse effects on the breastfed infant from Sodium Phenylacetate and Sodium Benzoate Injection or from the underlying maternal condition. 8.4 Pediatric Use Sodium Phenylacetate and Sodium Benzoate Injection has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [ see Dosage and Administration (2) ]. 8.5 Geriatric Use Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population. 8.6 Gender Pharmacokinetic parameters of Sodium Phenylacetate and Sodium Benzoate Injection were compared in healthy males and females. Bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. However, conclusions cannot be drawn due to the limited number of subjects in this study. 8.7 Hepatic Insufficiency Limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. However, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. Therefore, caution should be used in administering Sodium Phenylacetate and Sodium Benzoate Injection to patients with hepatic insufficiency. 8.8 Renal Impairment The drug metabolites of Sodium Phenylacetate and Sodium Benzoate Injection (phenylacetylglutamine and hippurate) and subsequently ammonia are primarily excreted by the kidney. Therefore, use caution and closely monitor patients with impaired renal function who receive Sodium Phenylacetate and Sodium Benzoate Injection."],"dosage_and_administration_table":["
Table 1: Dosage and Administration
Abbreviations: CPS - carbamyl phosphate synthetase; OTC - ornithine transcarbamylase; ASS - argininosuccinate synthetase; ASL - argininosuccinate lyase
Patient Population Components of Infusion Solution Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection at ≥ 25 mL/Kg before administration. Dosage Provided
Sodium Phenylacetate and Sodium Benzoate Injection Arginine HCl Injection, 10% Sodium Phenylacetate Sodium Benzoate Arginine HCl
CPS and OTC Deficiency
Patients 0 to 20 kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 2 mL/kg 250 mg/kg 250 mg/kg 200 mg/kg
ASS and ASL Deficiency
Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 6 mL/kg 250 mg/kg 250 mg/kg 600 mg/kg
CPS and OTC Deficiency
Patient>20kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m2 2 mL/kg 5.5g/m2 5.5 g/m2 200 mg/kg
ASS and ASL Deficiency
Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m2 6 mL/kg 5.5 g/m2 5.5 g/m2 600 mg/kg
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Vial Carton vial-label carton-label"]},"tags":[{"label":"sodium benzoate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase 2","category":"target"},{"label":"CA2","category":"gene"},{"label":"CA4","category":"gene"},{"label":"A16AX11","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Topical","category":"route"},{"label":"Injection","category":"form"},{"label":"Liquid","category":"form"},{"label":"Shampoo","category":"form"},{"label":"Spray","category":"form"},{"label":"Active","category":"status"},{"label":"Apnea in the newborn","category":"indication"},{"label":"Hyperammonemia","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antifungal Agents","category":"pharmacology"},{"label":"Food Additives","category":"pharmacology"},{"label":"Food Preservatives","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":170.567,"date":"","count":40,"signal":"Creatinine renal clearance decreased","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=171)"},{"llr":151.706,"date":"","count":35,"signal":"Sedation complication","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=152)"},{"llr":147.556,"date":"","count":40,"signal":"Blood calcium decreased","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=148)"},{"llr":139.235,"date":"","count":43,"signal":"Orthostatic hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=139)"},{"llr":118.782,"date":"","count":41,"signal":"Cognitive disorder","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=119)"},{"llr":110.935,"date":"","count":36,"signal":"Sedation","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=111)"},{"llr":107.76,"date":"","count":25,"signal":"Hyperammonaemia","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=108)"},{"llr":103.948,"date":"","count":39,"signal":"Depressed level of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=104)"},{"llr":97.12,"date":"","count":39,"signal":"Balance disorder","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=97)"},{"llr":85.417,"date":"","count":38,"signal":"Mobility decreased","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=85)"},{"llr":64.919,"date":"","count":42,"signal":"Constipation","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=65)"}],"commonSideEffects":[{"effect":"Creatinine renal clearance decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sedation complication","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood calcium decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Orthostatic hypotension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cognitive disorder","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hyperammonaemia","drugRate":"LLR 108","severity":"common","_validated":true},{"effect":"Depressed level of consciousness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Balance disorder","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Mobility decreased","drugRate":"LLR 85","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Acute nephropathy","Agoraphobia","Body fluid retention","CNS Toxicity","Chronic heart failure","Conduction disorder of the heart","Disease of liver","Edema","Hepatic failure","Hyperglycemia","Hypertensive disorder","Hypokalemia","Impaired renal function disorder","Insomnia","Kidney disease","Metabolic acidosis","Myocardial infarction in recovery phase","Myocardial ischemia","Necrotizing enterocolitis in fetus OR newborn","Obsessive-compulsive disorder","Panic disorder","Peptic ulcer","Seizure disorder"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SODIUM BENZOATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:46:45.275642+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:46:51.205012+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM BENZOATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:46:51.906238+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:44.163072+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:44.163099+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1356/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:53.253996+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217526","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:46:44.163102+00:00"}},"allNames":"ammonul","offLabel":[],"synonyms":["sodium benzoate"],"timeline":[{"date":"1987-12-23","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Ammonul (Sodium Benzoate) is a small molecule drug that targets carbonic anhydrase 2. It is a sodium benzoate drug class, FDA approved in 1987 for the treatment of apnea in the newborn and hyperammonemia. The commercial status of Ammonul is not publicly available. Key safety considerations include the potential for adverse effects, although specific details are not provided. As a sodium benzoate, it is a generic drug class.","approvals":[{"date":"1987-12-23","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Ammonul","ecosystem":[{"indication":"Apnea in the newborn","otherDrugs":[{"name":"caffeine","slug":"caffeine","company":"Novartis"}],"globalPrevalence":null},{"indication":"Hyperammonemia","otherDrugs":[{"name":"benzoic acid","slug":"benzoic-acid","company":""},{"name":"lactulose","slug":"lactulose","company":""},{"name":"phenylacetic acid","slug":"phenylacetic-acid","company":"B Braun"}],"globalPrevalence":null}],"mechanism":{"target":"Carbonic anhydrase 2","novelty":"Follow-on","targets":[{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA4","source":"DrugCentral","target":"Carbonic anhydrase 4","protein":"Carbonic anhydrase 4"}],"modality":"Small Molecule","drugClass":"sodium benzoate","explanation":"Think of ammonia like a toxic gas in your body. Carbonic anhydrase 2 helps to make more ammonia. Ammonul blocks this enzyme, so less ammonia is made, which can help treat conditions like hyperammonemia.","oneSentence":"Ammonul works by inhibiting the enzyme carbonic anhydrase 2, which helps to reduce ammonia levels in the body.","technicalDetail":"Ammonul (sodium benzoate) acts as a competitive inhibitor of carbonic anhydrase 2, thereby reducing the enzyme's activity and subsequent production of ammonia.","_target_confidence":0.5},"commercial":{"launchDate":"1987","_launchSource":"DrugCentral (FDA 1987-12-23, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4373","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SODIUM%20BENZOATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM BENZOATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:40:15.805966","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:57.000638+00:00","fieldsConflicting":9,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"thioctic acid","drugSlug":"thioctic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"phenylbutanoic acid","drugSlug":"phenylbutanoic-acid","fdaApproval":"1996-04-30","relationship":"same-class"},{"drugName":"nitisinone","drugSlug":"nitisinone","fdaApproval":"2002-01-18","patentExpiry":"Jan 5, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"zinc acetate","drugSlug":"zinc-acetate","fdaApproval":"1980-02-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"miglustat","drugSlug":"miglustat","fdaApproval":"2003-07-31","patentExpiry":"Sep 30, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sapropterin","drugSlug":"sapropterin","fdaApproval":"2007-12-13","patentExpiry":"Nov 1, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"teduglutide","drugSlug":"teduglutide","fdaApproval":"2012-12-21","patentExpiry":"May 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"glycerol phenylbutyrate","drugSlug":"glycerol-phenylbutyrate","fdaApproval":"2013-02-01","patentExpiry":"Sep 22, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eliglustat","drugSlug":"eliglustat","fdaApproval":"2014-08-19","patentExpiry":"Nov 24, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"trientine","drugSlug":"trientine","fdaApproval":"1985-11-08","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"uridine triacetate","drugSlug":"uridine-triacetate","fdaApproval":"2015-09-04","patentExpiry":"Aug 17, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"migalastat","drugSlug":"migalastat","fdaApproval":"2018-08-08","patentExpiry":"Oct 20, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"givosiran","drugSlug":"givosiran","fdaApproval":"2019-11-20","patentExpiry":"Oct 3, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"triheptanoin","drugSlug":"triheptanoin","fdaApproval":"2020-06-30","patentExpiry":"Nov 14, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lumasiran","drugSlug":"lumasiran","fdaApproval":"2020-11-23","patentExpiry":"Oct 9, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fosdenopterin","drugSlug":"fosdenopterin","fdaApproval":"2021-02-26","patentExpiry":"Apr 9, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lonafarnib","drugSlug":"lonafarnib","fdaApproval":"2020-11-20","patentExpiry":"Jul 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"phenylacetic acid","drugSlug":"phenylacetic-acid","fdaApproval":"1987-12-23","relationship":"same-class"}],"genericName":"sodium benzoate","indications":{"approved":[{"name":"Apnea in the newborn","source":"DrugCentral","snomedId":13094009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Hyperammonemia","source":"DrugCentral","snomedId":9360008,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[{"name":"Drowsy","source":"DrugCentral","drugName":"SODIUM BENZOATE"},{"name":"Fatigue","source":"DrugCentral","drugName":"SODIUM BENZOATE","evidenceCount":5,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"thioctic-acid","brandName":"thioctic acid","genericName":"thioctic acid","approvalYear":"","relationship":"same-class"},{"drugId":"phenylbutanoic-acid","brandName":"phenylbutanoic acid","genericName":"phenylbutanoic acid","approvalYear":"1996","relationship":"same-class"},{"drugId":"nitisinone","brandName":"nitisinone","genericName":"nitisinone","approvalYear":"2002","relationship":"same-class"},{"drugId":"zinc-acetate","brandName":"zinc acetate","genericName":"zinc acetate","approvalYear":"1980","relationship":"same-class"},{"drugId":"miglustat","brandName":"miglustat","genericName":"miglustat","approvalYear":"2003","relationship":"same-class"},{"drugId":"sapropterin","brandName":"sapropterin","genericName":"sapropterin","approvalYear":"2007","relationship":"same-class"},{"drugId":"teduglutide","brandName":"teduglutide","genericName":"teduglutide","approvalYear":"2012","relationship":"same-class"},{"drugId":"glycerol-phenylbutyrate","brandName":"glycerol phenylbutyrate","genericName":"glycerol phenylbutyrate","approvalYear":"2013","relationship":"same-class"},{"drugId":"eliglustat","brandName":"eliglustat","genericName":"eliglustat","approvalYear":"2014","relationship":"same-class"},{"drugId":"trientine","brandName":"trientine","genericName":"trientine","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05006781","phase":"PHASE2","title":"The Dose Finding Study of DAOIB Added to tDCS for AD","status":"SUSPENDED","sponsor":"Chang Gung Memorial Hospital","startDate":"2027-01","conditions":["Transcranial Direct Current Stimulation","Dementia"],"enrollment":140,"completionDate":"2028-12"},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":["Heart Failure"],"enrollment":46,"completionDate":"2025-05-22"},{"nctId":"NCT04966507","phase":"PHASE2","title":"Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-02-17","conditions":["Gonorrhea"],"enrollment":89,"completionDate":"2025-12-12"},{"nctId":"NCT06980636","phase":"PHASE4","title":"A Trial of Shengmai Liquid for Long COVID Fatigue.","status":"RECRUITING","sponsor":"Beijing University of Chinese Medicine","startDate":"2025-12-01","conditions":["Long COVID Fatigue"],"enrollment":100,"completionDate":"2026-11-30"},{"nctId":"NCT03620773","phase":"PHASE1,PHASE2","title":"Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-10-01","conditions":["Type 2 Diabetes Mellitus","Obesity","Bariatric Surgery Candidate","Nephropathy","Diabetic Kidney Disease","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes Complications","Weight Loss","Diabetic Nephropathies","Adolescent Obesity","Pediatric Obesity"],"enrollment":24,"completionDate":"2024-09-25"},{"nctId":"NCT05114096","phase":"PHASE4","title":"Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2023-07-20","conditions":["Preterm Birth","Premature Birth","Complication of Prematurity","Obstetric Labor, Premature","Pregnancy Complications"],"enrollment":3254,"completionDate":"2029-12-31"},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":["Cardiovascular Events","Type2 Diabetes","Renal Disease"],"enrollment":781430,"completionDate":"2026-07-01"},{"nctId":"NCT01426529","phase":"PHASE1","title":"Caveolin-1 and Vascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-10-01","conditions":["Hypertension","Insulin Resistance"],"enrollment":120,"completionDate":"2026-10-15"},{"nctId":"NCT07240051","phase":"NA","title":"Efficacy of Different Types of Chemical Peels in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Nahla Maher Mahmoud Mahran","startDate":"2024-03-09","conditions":["Acne","Peeling"],"enrollment":90,"completionDate":"2024-07-12"},{"nctId":"NCT04155567","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-11-13","conditions":["Healthy Volunteers"],"enrollment":10,"completionDate":"2019-12-06"},{"nctId":"NCT05464940","phase":"NA","title":"Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-09","conditions":["Atrial Fibrillation"],"enrollment":100,"completionDate":"2026-06"},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":["Heart Failure"],"enrollment":46,"completionDate":"2025-07-30"},{"nctId":"NCT02546583","phase":"PHASE1","title":"Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-08-31","conditions":["Heart Failure"],"enrollment":458,"completionDate":"2020-01-23"},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":["Acute Heart Failure","Diuretics Drug Reactions"],"enrollment":107,"completionDate":"2024-07-01"},{"nctId":"NCT05507892","phase":"PHASE2","title":"Renal Mechanism of SGLT2 Inhibition","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-10-10","conditions":["Type 2 Diabetes","Diabetic Kidney Disease"],"enrollment":40,"completionDate":"2026-12-15"},{"nctId":"NCT03469011","phase":"PHASE1","title":"A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2018-09-18","conditions":["Papillary Thyroid Cancer"],"enrollment":14,"completionDate":"2024-07-31"},{"nctId":"NCT05065372","phase":"PHASE1","title":"MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes","status":"RECRUITING","sponsor":"Kalie Tommerdahl","startDate":"2022-07-01","conditions":["Type 1 Diabetes","Diabetic Kidney Disease","Cardiovascular Diseases","Endothelial Dysfunction","Insulin Sensitivity"],"enrollment":60,"completionDate":"2027-07-31"},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":112,"completionDate":"2020-03"},{"nctId":"NCT03229408","phase":"PHASE2","title":"Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2018-12-05","conditions":["Polycystic Ovary Syndrome"],"enrollment":60,"completionDate":"2024-02-28"},{"nctId":"NCT06374641","phase":"NA","title":"The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2024-03-26","conditions":["Exercise Performance","Cognitive Function"],"enrollment":40,"completionDate":"2025-10"},{"nctId":"NCT06969495","phase":"NA","title":"Pilot Clinical Study Testing Tiger Milk Mushroom Gel (Lignosus Rhinocerus TM02®) for Treating Mouth Ulcers","status":"COMPLETED","sponsor":"Mahsa University","startDate":"2023-02-01","conditions":["Mouth Ulcer"],"enrollment":21,"completionDate":"2024-02-23"},{"nctId":"NCT05684276","phase":"PHASE2","title":"DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2023-05-12","conditions":["NSCLC","Pancoast Tumor"],"enrollment":22,"completionDate":"2028-06-01"},{"nctId":"NCT05012254","phase":"PHASE2","title":"Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-11-18","conditions":["Non Small Cell Lung Cancer","Brain Metastases, Adult","Lung Cancer"],"enrollment":71,"completionDate":"2026-12-15"},{"nctId":"NCT05008276","phase":"","title":"Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)","status":"RECRUITING","sponsor":"Petter Bjornstad","startDate":"2021-09-27","conditions":["Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Adolescent Obesity","Pre Diabetes","Kidney Hypoxia","Puberty"],"enrollment":100,"completionDate":"2027-12-01"},{"nctId":"NCT05102591","phase":"PHASE3","title":"A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2022-02-22","conditions":["Migraine Disorders"],"enrollment":22,"completionDate":"2024-08-29"},{"nctId":"NCT06793267","phase":"PHASE3","title":"Ultrasound Assessment of Metoclopramide's Effect on Stomach Volume in Urgent Pediatric Trauma Surgery","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-02-15","conditions":["Gastric Volume"],"enrollment":70,"completionDate":"2026-03-15"},{"nctId":"NCT00597909","phase":"PHASE2","title":"Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Amgen","startDate":"2007-12","conditions":["Hepatic Encephalopathy"],"enrollment":1,"completionDate":"2008-09"},{"nctId":"NCT05129722","phase":"PHASE4","title":"Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial","status":"TERMINATED","sponsor":"The George Institute","startDate":"2022-10-01","conditions":["Heart Failure With Preserved Ejection Fraction"],"enrollment":3,"completionDate":"2024-05-01"},{"nctId":"NCT06626984","phase":"PHASE1,PHASE2","title":"Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis","status":"NOT_YET_RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2024-12-01","conditions":["Sepsis","Fluid Overload","Endothelial Dysfunction","Microcirculation"],"enrollment":65,"completionDate":"2026-07-01"},{"nctId":"NCT05923723","phase":"NA","title":"Efficacy of a Dietary Intervention for the Treatment of Constipation in Institutionalized Older Adults. Medellín, 2023-2024.","status":"COMPLETED","sponsor":"CES University","startDate":"2024-03-15","conditions":["Constipation Chronic Idiopathic"],"enrollment":56,"completionDate":"2024-06-25"},{"nctId":"NCT03689946","phase":"PHASE3","title":"Effect of Evolocumab on Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-03-19","conditions":["Cardiovascular Disease","Hyperlipidemia"],"enrollment":55,"completionDate":"2023-05-30"},{"nctId":"NCT01948427","phase":"","title":"Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-09-25","conditions":["Urea Cycle Disorder"],"enrollment":203,"completionDate":"2020-02-24"},{"nctId":"NCT00977600","phase":"PHASE1","title":"A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2005-07"},{"nctId":"NCT01908192","phase":"PHASE2,PHASE3","title":"Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®","status":"TERMINATED","sponsor":"SyneuRx International (Taiwan) Corp","startDate":"2014-06","conditions":["Schizophrenia"],"enrollment":60,"completionDate":"2023-10-26"},{"nctId":"NCT06182319","phase":"PHASE3","title":"Optimizing Treatment of Adhesive Small Bowel Obstruction","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-01-01","conditions":["Adhesive Small Bowel Obstruction"],"enrollment":40,"completionDate":"2025-12-15"},{"nctId":"NCT06358911","phase":"PHASE4","title":"A Clinical Study for the Effect of 4th Generation Poly AmidoAmine Dendrimer on Post-Bleaching Hypersensitivity and Shade Stability","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-13","conditions":["Tooth Hypersensitivity"],"enrollment":60,"completionDate":"2023-09-10"},{"nctId":"NCT06340789","phase":"PHASE2","title":"Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-04-10","conditions":["Symptom, Cognitive","Schizophrenia","Schizo Affective Disorder"],"enrollment":90,"completionDate":"2025-04-30"},{"nctId":"NCT05319990","phase":"","title":"Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-03-09","conditions":["Type 1 Diabetes","Diabetic Kidney Disease","Diabetes Complications","Diabetic Nephropathies","Autoimmune Diabetes"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT06122467","phase":"NA","title":"A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms","status":"COMPLETED","sponsor":"Menning Labs","startDate":"2023-10-02","conditions":["Acne"],"enrollment":36,"completionDate":"2023-12-31"},{"nctId":"NCT06148662","phase":"PHASE4","title":"The Effect of Oral Sprays on Salivary pH","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2023-12-01","conditions":["Oral Health"],"enrollment":33,"completionDate":"2024-01-25"},{"nctId":"NCT05726097","phase":"PHASE3","title":"Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure","status":"COMPLETED","sponsor":"Region Skane","startDate":"2023-02-01","conditions":["Colon Cancer","Inflammatory Bowel Diseases","Gastrointestinal Bleed","Colon Polyp"],"enrollment":147,"completionDate":"2023-10-31"},{"nctId":"NCT06235021","phase":"NA","title":"Clinical Efficacy of Saffron Mouth Rinse in Periodontitis Patients With Renal Disease","status":"UNKNOWN","sponsor":"British University In Egypt","startDate":"2024-01-01","conditions":["Periodontal Diseases","Periodontal Pocket","Periodontal Inflammation"],"enrollment":20,"completionDate":"2024-03-01"},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":["Heart Failure, Congestive"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT03573921","phase":"PHASE2,PHASE3","title":"Gastrografin for Treating Small Bowel Obstruction in Children","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-09-01","conditions":["Small Bowel Obstruction"],"enrollment":2,"completionDate":"2022-12-19"},{"nctId":"NCT03334578","phase":"PHASE4","title":"The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2018-08-03","conditions":["Gastroschisis","Bowel Obstruction","Birth Defect"],"enrollment":0,"completionDate":"2020-12-17"},{"nctId":"NCT04997811","phase":"PHASE2","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Prof. Janet Dunn","startDate":"2021-12-21","conditions":["Myelodysplastic Syndromes (MDS)"],"enrollment":120,"completionDate":"2025-06-30"},{"nctId":"NCT05906303","phase":"PHASE1","title":"Caffeine in the Second Stage of Labor in Low-risk Nulliparous Mothers at Term","status":"UNKNOWN","sponsor":"The Reading Hospital and Medical Center","startDate":"2023-12-01","conditions":["Second Stage of Labor"],"enrollment":80,"completionDate":"2025-02-01"},{"nctId":"NCT04494529","phase":"PHASE3","title":"Single Dose Antenatal Corticosteroids (SNACS) for Women at Risk of Preterm Birth","status":"COMPLETED","sponsor":"McMaster University","startDate":"2021-03-01","conditions":["Preterm Birth","Complication of Prematurity","Obstetric Labor, Premature","Obstetric Labor Complications","Pregnancy Complications"],"enrollment":30,"completionDate":"2021-08-31"},{"nctId":"NCT03584217","phase":"PHASE1,PHASE2","title":"Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2018-10-01","conditions":["Type 2 Diabetes Mellitus","Obesity","Nephropathy","Adolescent Obesity"],"enrollment":100,"completionDate":"2023-10-30"},{"nctId":"NCT04910906","phase":"","title":"Non-Interventional Multicentre Post-market Study of Ectoin® Vaginal Gel for Symptomatic Treatment of Vaginal Atrophy","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2021-05-03","conditions":["Vaginal Atrophy"],"enrollment":155,"completionDate":"2022-02-09"},{"nctId":"NCT05746377","phase":"PHASE4","title":"Metoclopramide in Upper Gastrointestinal Bleed","status":"UNKNOWN","sponsor":"Mercy Health System","startDate":"2023-05-20","conditions":["Upper GI Bleeding","Bleeds Gastric","Bleed Ulcer","Hemorrhage Gastric","Hemorrhage; Ulcer"],"enrollment":60,"completionDate":"2024-06"},{"nctId":"NCT00335140","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2007-08-23","conditions":["Lymphoma"],"enrollment":26,"completionDate":"2015-07"},{"nctId":"NCT04146038","phase":"PHASE2","title":"Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-10-26","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia"],"enrollment":5,"completionDate":"2022-10-25"},{"nctId":"NCT05841173","phase":"NA","title":"Effects of Weight Loss Management on Cognitive Function in Elderly Women With Obesity","status":"UNKNOWN","sponsor":"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","startDate":"2022-01-09","conditions":["Obesity","Cognitive Change"],"enrollment":200,"completionDate":"2023-12-30"},{"nctId":"NCT04542473","phase":"PHASE2,PHASE3","title":"Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-07-01","conditions":["SEPSIS","MALNUTRITION, CHILD"],"enrollment":400,"completionDate":"2024-06-30"},{"nctId":"NCT04074668","phase":"","title":"Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-01","conditions":["Diabetic Kidney Disease","Type 1 Diabetes","Diabetes","Diabetes Mellitus","Diabetes Complications","Diabetic Nephropathies","Type1diabetes","Diabetes, Autoimmune","Autoimmune Diabetes","Juvenile Diabetes","Type 1 Diabetes Mellitus"],"enrollment":58,"completionDate":"2022-11-15"},{"nctId":"NCT04407481","phase":"","title":"PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-11-01","conditions":["Polycystic Kidney Disease, Adult","Polycystic Kidney, Autosomal Dominant"],"enrollment":22,"completionDate":"2022-10-13"},{"nctId":"NCT02769494","phase":"PHASE3","title":"The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-03","conditions":["Crohn's Disease","Oral Ulcer"],"enrollment":0,"completionDate":"2017-01"},{"nctId":"NCT02537314","phase":"PHASE1","title":"Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-09","conditions":["Obesity"],"enrollment":27,"completionDate":"2022-12-08"},{"nctId":"NCT05626881","phase":"NA","title":"Efficacy of Intralesional PRP +/- Topical Silymarin in the Treatment of Melasma","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-05-01","conditions":["Melasma"],"enrollment":60,"completionDate":"2022-12-01"},{"nctId":"NCT01511042","phase":"","title":"Vascular Dysfunction in Diabetes: Genes and Hormones","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"1999-12","conditions":["Diabetes Mellitus"],"enrollment":100,"completionDate":"2020-06"},{"nctId":"NCT05530356","phase":"","title":"Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study","status":"ENROLLING_BY_INVITATION","sponsor":"University of Colorado, Denver","startDate":"2022-09-30","conditions":["Type 2 Diabetes","Diabetes Type 2","Diabetic Nephropathies","Nephropathy","Obesity","Adolescent Obesity","Diabetic Kidney Disease"],"enrollment":100,"completionDate":"2029-05"},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":["Schizophrenia"],"enrollment":145,"completionDate":"2021-08-30"},{"nctId":"NCT04969120","phase":"PHASE4","title":"Metoclopramide and the Length of First Stage of Labor , a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-01","conditions":["Labour Duration and Metoclopramide"],"enrollment":80,"completionDate":"2022-07-01"},{"nctId":"NCT05475314","phase":"NA","title":"Effect of Postbiotic Product on Colonic Barriers in IBS","status":"COMPLETED","sponsor":"Nordisk Rebalance A/S","startDate":"2020-12-01","conditions":["IBS - Irritable Bowel Syndrome"],"enrollment":30,"completionDate":"2022-04-30"},{"nctId":"NCT01156220","phase":"PHASE4","title":"Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers","status":"WITHDRAWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2012-01","conditions":["Healthy Male and Female Volunteers"],"enrollment":0,"completionDate":"2012-06"},{"nctId":"NCT04697485","phase":"PHASE4","title":"Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-01-08","conditions":["HF - Heart Failure","Diabetes Mellitus"],"enrollment":0,"completionDate":"2022-03-30"},{"nctId":"NCT04492839","phase":"NA","title":"Intestinal Adsorbent and Breath Gas Levels","status":"COMPLETED","sponsor":"Dr Anthony Hobson","startDate":"2019-08-13","conditions":["Gastroesophageal Reflux","Small Intestinal Bacterial Overgrowth"],"enrollment":20,"completionDate":"2020-12-01"},{"nctId":"NCT03510741","phase":"PHASE2","title":"Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.","status":"COMPLETED","sponsor":"Pakistan Institute of Living and Learning","startDate":"2019-01-01","conditions":["Schizophrenia","Schizophreniform Disorders","Schizoaffective Disorder"],"enrollment":64,"completionDate":"2021-03-30"},{"nctId":"NCT03618420","phase":"PHASE1,PHASE2","title":"Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-10-01","conditions":["Diabetes Mellitus, Type 1","Nephropathy","Diabetic Nephropathies","Juvenile Diabetes","Diabetes Mellitus Complication","Autoimmune Diabetes","Type 1 Diabetes Mellitus"],"enrollment":50,"completionDate":"2021-08-01"},{"nctId":"NCT05312190","phase":"NA","title":"Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-03-15","conditions":["Menstrual Disorders"],"enrollment":330,"completionDate":"2023-06-30"},{"nctId":"NCT03107871","phase":"PHASE2","title":"Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert Park","startDate":"2018-08-31","conditions":["Cmv Congenital","CMV","Congenital Cmv","SNHL","Sensorineural Hearing Loss"],"enrollment":52,"completionDate":"2024-07"},{"nctId":"NCT04492241","phase":"NA","title":"Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-05","conditions":["Motoric Cognitive Risk Syndrome","Mild Cognitive Impairment","Aging","Locomotive Syndrome"],"enrollment":800,"completionDate":"2024-12-31"},{"nctId":"NCT05139966","phase":"PHASE2,PHASE3","title":"Fluoride Controlled-release System for Initial Lesions of Caries","status":"COMPLETED","sponsor":"Federal University of Paraíba","startDate":"2017-08-03","conditions":["White Spot Lesion"],"enrollment":21,"completionDate":"2018-12-12"},{"nctId":"NCT04902105","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-05-13","conditions":["Drug Interaction"],"enrollment":38,"completionDate":"2021-07-06"},{"nctId":"NCT04884464","phase":"","title":"Hyaluronic Acid in Counteracting Aphthous Stomatitis","status":"COMPLETED","sponsor":"University of Urbino \"Carlo Bo\"","startDate":"2018-09-01","conditions":["Aphthous Stomatitis"],"enrollment":49,"completionDate":"2019-06-30"},{"nctId":"NCT04710888","phase":"PHASE2","title":"Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-01-01","conditions":["Oral Ulcer"],"enrollment":30,"completionDate":"2021-12-01"},{"nctId":"NCT01456208","phase":"","title":"Genetic Mechanisms in Human Hypertension","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"1999-10","conditions":["Hypertension"],"enrollment":150,"completionDate":"2020-06"},{"nctId":"NCT04872946","phase":"NA","title":"Topical and Oral Regimen for Skin Health","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2019-11-26","conditions":["Skin Abnormalities"],"enrollment":74,"completionDate":"2020-05-07"},{"nctId":"NCT03331965","phase":"PHASE2","title":"Metoclopramide Versus Placebo for GJ Placement","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-04-09","conditions":["Radiation Exposure","Enteral Nutrition"],"enrollment":110,"completionDate":"2019-10-03"},{"nctId":"NCT02913469","phase":"PHASE4","title":"Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2014-12-12","conditions":["ST-segment Elevation Myocardial Infarction"],"enrollment":128,"completionDate":"2020-08-15"},{"nctId":"NCT03380754","phase":"NA","title":"Effects of Preoperative Carbohydrate Rich Drinks on Immediate Postoperative Outcome in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2017-07-15","conditions":["Post Operative Nausea and Vomiting"],"enrollment":150,"completionDate":"2019-08-01"},{"nctId":"NCT00330733","phase":"PHASE2,PHASE3","title":"Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2007-01","conditions":["Atherosclerosis","Cardiovascular Disease","Inflammation","Insulin Resistance","Noninsulin-dependent Diabetes Mellitus"],"enrollment":71,"completionDate":"2010-09"},{"nctId":"NCT03838068","phase":"PHASE2,PHASE3","title":"Pulpotomy Technique Preserving Vitality of Traumatized Anterior Permanent Immature Teeth","status":"COMPLETED","sponsor":"Gihan M Abuelniel ,PhD","startDate":"2017-01-18","conditions":["Pulp Exposure, Dental"],"enrollment":33,"completionDate":"2019-08-15"},{"nctId":"NCT03477903","phase":"PHASE2","title":"TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2018-08-25","conditions":["Critical Illness","Enteral Nutrition","Enteral Feeding Intolerance"],"enrollment":1,"completionDate":"2018-08-29"},{"nctId":"NCT02627950","phase":"PHASE4","title":"Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2015-12","conditions":["Acute Myocardial Infarction"],"enrollment":138,"completionDate":"2018-10"},{"nctId":"NCT04022941","phase":"NA","title":"Efficacy and Safety of Sodium Benzoate in the Management of Hyperammonemia in Infants, Children and Adolescent With Chronic Liver Disease.","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2017-04-01","conditions":["Chronic Liver Disease"],"enrollment":108,"completionDate":"2018-12-31"},{"nctId":"NCT00891527","phase":"PHASE1,PHASE2","title":"Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-10","conditions":["Pulmonary Veno Occlusive Disease"],"enrollment":50,"completionDate":"2015-12"},{"nctId":"NCT01973335","phase":"PHASE4","title":"Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2013-11","conditions":["Heart Failure"],"enrollment":34,"completionDate":"2017-10"},{"nctId":"NCT02726620","phase":"NA","title":"Decision Support for Intraoperative Low Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-01-05","conditions":["Hypotension"],"enrollment":22435,"completionDate":"2018-12-29"},{"nctId":"NCT02930005","phase":"PHASE2","title":"Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-08-07","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder"],"enrollment":8,"completionDate":"2016-10-06"},{"nctId":"NCT03819179","phase":"NA","title":"The Influence of Personal Care Products on the Skin Microbiome","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2017-12-01","conditions":["Microbiome"],"enrollment":30,"completionDate":"2018-02-06"},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":["Nausea","Vomiting"],"enrollment":494,"completionDate":"2014-08-04"},{"nctId":"NCT01205529","phase":"NA","title":"ST-segment Elevation as an AF Endophenotype","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-11","conditions":["Atrial Fibrillation"],"enrollment":161,"completionDate":"2015-06"},{"nctId":"NCT02111200","phase":"NA","title":"Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-09","conditions":["Urea Cycle Disorders, Inborn"],"enrollment":7,"completionDate":"2015-10"},{"nctId":"NCT03383315","phase":"PHASE2","title":"Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2017-07-01","conditions":["Trauma","Opioid Analgesic Adverse Reaction"],"enrollment":191,"completionDate":"2017-09-30"},{"nctId":"NCT01067677","phase":"NA","title":"Rescue Emetic Therapy for Children Having Elective Surgery","status":"WITHDRAWN","sponsor":"Franklyn Cladis","startDate":"2010-02","conditions":["Post Operative Nausea and Vomiting","Rescue Emetic Therapy"],"enrollment":0,"completionDate":"2014-02"},{"nctId":"NCT03287011","phase":"NA","title":"Efficacy of a Plaque Disclosing Toothpaste on Home Oral Hygiene Procedures","status":"UNKNOWN","sponsor":"Segi University","startDate":"2017-09-11","conditions":["Chronic Gingivitis, Plaque Induced"],"enrollment":50,"completionDate":"2018-04-30"},{"nctId":"NCT01702688","phase":"NA","title":"Evaluation of Lysine-Specific Demethylase 1","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2012-07","conditions":["Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT00478556","phase":"PHASE4","title":"Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-08","conditions":["Healthy"],"enrollment":300,"completionDate":"2009-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Liquid, Shampoo, Spray","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Sodium Phenylacetate and Sodium Benzoate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"SODIUM PHENYLACETATE AND SODIUM BENZOATE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"SODIUM PHENYLACETATE and SODIUM BENZOATE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Sodium Phenylacetate and Sodium Benzoate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Sodium Phenylacetate and sodium benzoate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Ammonul"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"SODIUM PHENYLACETATE AND SODIUM BENZOATE"},{"form":"LIQUID","route":"TOPICAL","productName":"Oriox Cool Breath Oral Rinse Mild"},{"form":"LIQUID","route":"TOPICAL","productName":"s panax all in one mist"},{"form":"LIQUID","route":"TOPICAL","productName":"s panax mist"},{"form":"LIQUID","route":"TOPICAL","productName":"s panax mist for refill"},{"form":"LIQUID","route":"TOPICAL","productName":"seo jeong ho hwang chill mist"},{"form":"LIQUID","route":"TOPICAL","productName":"seo jeong ho hwang chill deodorant"},{"form":"SHAMPOO","route":"TOPICAL","productName":"BEVERHILL Micro-Biome Scalp Cooling Essence (Prevention of hair loss, Trouble scalp treatment, Treatment of itching)"},{"form":"SPRAY","route":"TOPICAL","productName":"BEVERHILL HAIR TONIC"}]},"crossReferences":{"NUI":"N0000146158","MMSL":"5206","NDDF":"001243","UNII":"OJ245FE5EU","VUID":"4017797","CHEBI":"CHEBI:113455","VANDF":"4017797","RXNORM":"56455","UMLSCUI":"C0142805","chemblId":"CHEMBL1356","ChEMBL_ID":"CHEMBL1356","KEGG_DRUG":"D02277","PUBCHEM_CID":"517055","SNOMEDCT_US":"125706008","MESH_DESCRIPTOR_UI":"D020160"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1696,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A16AX11","allCodes":["A16AX11","A16AX30","V04CG30"]},"biosimilarFilings":[],"recentPublications":[],"combinationProducts":[{"brandName":"Ammonul","ingredients":"phenylacetic acid + sodium benzoate"},{"brandName":"Sodium Phenylacetate and Sodium Benzoate","ingredients":"phenylacetic acid + sodium benzoate"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1987","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-12-23T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:57.000638+00:00","fieldsConflicting":9,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}